Aimmune Therapeutics

Aimmune Therapeutics is a clinical-stage biopharmaceutical company developing desensitization treatments to protect people with food allergies from the life-threatening consequences of accidental exposures to their allergens. We are currently conducting a Phase 3 study of our lead product, AR101 for the treatment of peanut allergy.
Type
Public
HQ
Brisbane, US
Founded
2011
Size (employees)
62 (est)+15%
Aimmune Therapeutics was founded in 2011 and is headquartered in Brisbane, US

Aimmune Therapeutics Office Locations

Aimmune Therapeutics has office in Brisbane
Brisbane, US

Aimmune Therapeutics Metrics

Aimmune Therapeutics Summary

Market capitalization

$943 m

Closing share price

$22.6
Aimmune Therapeutics's current market capitalization is $943 m.

Aimmune Therapeutics Market Value History

Aimmune Therapeutics Online Presence

Aimmune Therapeutics Company Life

You may also be interested in